Cargando…

Safety and efficacy of extended dosing intervals of denosumab in patients with solid cancers and bone metastases: a retrospective study

AIM: More than half of patients with breast, lung, or prostate cancer who have bone metastases have evidence of skeletal-related events (SREs). Denosumab is a fully human monoclonal antibody that binds to and neutralizes receptor activator of nuclear factor kappa-B ligand (RANKL) on osteoblasts and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abousaud, Aseala I., Barbee, Meagan S., Davis, Christine C., Caulfield, Sarah E., Wang, Zeyuan, Boykin, Alexa, Carthon, Bradley C., Gogineni, Keerthi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7768832/ https://www.ncbi.nlm.nih.gov/pubmed/33488782 http://dx.doi.org/10.1177/1758835920982859

Ejemplares similares

Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors
por: Brown-Glaberman, Ursa, et al.
Publicado: (2012)

Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany
por: Diel, Ingo, et al.
Publicado: (2020)

Denosumab administration for bone metastases from solid tumors: a retrospective cross-sectional study
por: Mizuta, Kohei, et al.
Publicado: (2023)

Efficacy and Safety of Denosumab Biosimilar QL1206 Versus Denosumab in Patients with Bone Metastases from Solid Tumors: A Randomized Phase III Trial
por: Li, Huiping, et al.
Publicado: (2023)

Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021)

Management of bone metastases in refractory prostate cancer – role of denosumab
por: Paller, Channing J, et al.
Publicado: (2012)

Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report
por: Tanikawa, Motoki, et al.
Publicado: (2020)

A Retrospective Observational Study of Risk Factors for Denosumab-Related Osteonecrosis of the Jaw in Patients with Bone Metastases from Solid Cancers
por: Okuma, Satoe, et al.
Publicado: (2020)

Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study
por: Diel, Ingo J., et al.
Publicado: (2022)

Giant Cell Tumor of Bone: Effect of Longer Dosing Intervals of Denosumab on Tumor Control and Bone-related Complications
por: Jiang, Cindy Y, et al.
Publicado: (2022)

Extended-Interval Gentamicin Dosing for Pulmonic Tularemia
por: Dietrich, Tyson, et al.
Publicado: (2019)

Pharmacodynamics of natalizumab extended interval dosing in MS
por: Zhovtis Ryerson, Lana, et al.
Publicado: (2020)

Denosumab: a new option in the treatment of bone metastases from urological cancers
por: Yuasa, Takeshi, et al.
Publicado: (2012)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis
por: Haslbauer, Ferdinand, et al.
Publicado: (2019)

Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva)
por: Joob, Beuy, et al.
Publicado: (2014)

A Retrospective Analysis of Denosumab for the Treatment of Bone Metastases in Chinese Patients With Breast Cancer
por: Li, Wei, et al.
Publicado: (2023)

Current approaches to the management of Her2-negative metastatic breast cancer
por: Gogineni, Keerthi, et al.
Publicado: (2012)

COVID pandemic and denosumab adherence
por: Minisola, S., et al.
Publicado: (2022)

Evaluation of Extended Interval Dosing Aminoglycosides in the Morbidly Obese Population
por: Ross, Ashley L., et al.
Publicado: (2013)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Denosumab and osteonecrosis of the jaw
por: Bower, Robert
Publicado: (2019)

Osteonecrosis of the jaw and denosumab
por: Goss, Alastair N
Publicado: (2022)

Denosumab and muscle performance
por: Rolvien, Tim, et al.
Publicado: (2022)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Rader, Michael, et al.
Publicado: (2012)

Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases
por: Xie, Jipan, et al.
Publicado: (2011)

Evaluation of risk of nephrotoxicity with high dose, extended-interval colistin administration
por: Dewan, Arun, et al.
Publicado: (2014)

Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
por: Bernabéu, Ignacio, et al.
Publicado: (2020)

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus
por: Wiederhold, Nathan P., et al.
Publicado: (2019)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
por: Zeichner, Simon B., et al.
Publicado: (2016)

Effectiveness of Bone Metastases Treatment by Sm-153 Oxabifore in Combination with Monoclonal Antibody Denosumab (Xgeva): First Experience
por: Rasulova, Nigora, et al.
Publicado: (2013)

Denosumab and Sunitinib in the treatment of giant-cell tumor of bone with pulmonary and bone metastases in an adolescent: A case report
por: Wang, Guannan, et al.
Publicado: (2019)

Predictors for development of denosumab-induced hypocalcaemia in cancer patients with bone metastases determined by ordered logistic regression analysis
por: Kanbayashi, Yuko, et al.
Publicado: (2021)

Risk factors associated with skeletal-related events following discontinuation of denosumab treatment among patients with bone metastases from solid tumors: A real-world machine learning approach
por: Jacobson, Dionna, et al.
Publicado: (2022)

Quadruple-negative breast cancer: novel implications for a new disease
por: Bhattarai, Shristi, et al.
Publicado: (2020)

Quadruple-Negative Breast Cancer: An Uneven Playing Field
por: Saini, Geetanjali, et al.
Publicado: (2020)

Extended-interval Dosing of Gentamicin for Treatment of Neonatal Sepsis in Developed and Developing Countries
por: Darmstadt, Gary L., et al.
Publicado: (2008)

Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
por: Ryerson, Lana Zhovtis, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pt6p2e199rbv3h3pnfjspg5icd